PluroGen™ Therapeutics, Inc.
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
| News Release |
FOR IMMEDIATE RELEASE Contact: Neal G. Koller
President & CEO
22 June 2007 Board of Directors
443 994 0101
PLUROGEN THERAPEUTICS INC. PRESENTS AT THE MID-ATLANTIC DIAMOND VENTURES FORUM
(Charlottesville, VA, June 22, 2007) – PluroGen Therapeutics, Inc. today announced it presented at the Mid
Atlantic Diamond Ventures Forum in Philadelphia, PA.
Neal G. Koller, President & CEO of PluroGen, made the presentation to an audience which included
investment banks, venture capital firms and angel investors. Commenting on the presentation, Mr. Koller
said, “The Mid Atlantic Diamond Ventures Forum gave PluroGen a terrific venue to meet and inform the
eastern Pennsylvania, Delaware and southern New Jersey investment communities of our activities,
progress and investment opportunity.”
About PluroGen Therapeutics, Inc.
Headquartered in Charlottesville, Va., PluroGen. is a biopharmaceutical company commercializing its patent-
protected technology platform of topical drug delivery materials, drug efficacy enhancement materials and
novel therapeutics into protected, advanced therapeutic products for simple and complex wound healing.
The product portfolio targets improved, protected therapies for the 6 Areas of Therapeutic Treatment (ATT)
of tissue healing (cleansing, infection, pain, inflammation, tissue salvage, tissue regeneration).
The company’s first two products, PluroGel Silver Sulfadiazine and TAG, are based on an advanced patent
protected topical drug delivery technology that has been successfully used in the U.Va. Medical Center on
more than 2,000 patients (approved through the UVA Medical Center’s internal pharmacy approval
process). PluroGen’s management and board of directors individually have more than 20 years of
experience working closely with the burn and wound care communities and the life science industry.
About Mid-Atlantic Diamond Ventures
Mid-Atlantic Diamond Ventures (MADV) was formed in 2006 by Diamond State Ventures, which supported
the Mid-Atlantic region's most promising science and technology start-up companies for nearly five years,
and the Innovation and Entrepreneurship Institute (IEI) of Temple University 's Fox School of Business.
Mid-Atlantic Diamond Ventures regularly hosts venture forums at partner institutions around the region as
well as delivers high-quality coaching and advisory services to technology and science entrepreneurs.
Statements included in this press release that are not historical in nature are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that
forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to
differ materially and which are identified from time to time in the Company’s reports filed with the U.S.
Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for
forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com
Information included on PluroGen Therapeutics, Inc website is not incorporated herein by reference or
otherwise.
President & CEO
22 June 2007 Board of Directors
443 994 0101
PLUROGEN THERAPEUTICS INC. PRESENTS AT THE MID-ATLANTIC DIAMOND VENTURES FORUM
(Charlottesville, VA, June 22, 2007) – PluroGen Therapeutics, Inc. today announced it presented at the Mid
Atlantic Diamond Ventures Forum in Philadelphia, PA.
Neal G. Koller, President & CEO of PluroGen, made the presentation to an audience which included
investment banks, venture capital firms and angel investors. Commenting on the presentation, Mr. Koller
said, “The Mid Atlantic Diamond Ventures Forum gave PluroGen a terrific venue to meet and inform the
eastern Pennsylvania, Delaware and southern New Jersey investment communities of our activities,
progress and investment opportunity.”
About PluroGen Therapeutics, Inc.
Headquartered in Charlottesville, Va., PluroGen. is a biopharmaceutical company commercializing its patent-
protected technology platform of topical drug delivery materials, drug efficacy enhancement materials and
novel therapeutics into protected, advanced therapeutic products for simple and complex wound healing.
The product portfolio targets improved, protected therapies for the 6 Areas of Therapeutic Treatment (ATT)
of tissue healing (cleansing, infection, pain, inflammation, tissue salvage, tissue regeneration).
The company’s first two products, PluroGel Silver Sulfadiazine and TAG, are based on an advanced patent
protected topical drug delivery technology that has been successfully used in the U.Va. Medical Center on
more than 2,000 patients (approved through the UVA Medical Center’s internal pharmacy approval
process). PluroGen’s management and board of directors individually have more than 20 years of
experience working closely with the burn and wound care communities and the life science industry.
About Mid-Atlantic Diamond Ventures
Mid-Atlantic Diamond Ventures (MADV) was formed in 2006 by Diamond State Ventures, which supported
the Mid-Atlantic region's most promising science and technology start-up companies for nearly five years,
and the Innovation and Entrepreneurship Institute (IEI) of Temple University 's Fox School of Business.
Mid-Atlantic Diamond Ventures regularly hosts venture forums at partner institutions around the region as
well as delivers high-quality coaching and advisory services to technology and science entrepreneurs.
Statements included in this press release that are not historical in nature are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that
forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to
differ materially and which are identified from time to time in the Company’s reports filed with the U.S.
Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for
forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com
Information included on PluroGen Therapeutics, Inc website is not incorporated herein by reference or
otherwise.